Navitoclax (ABT-263)

製品コードS1001

Navitoclax (ABT-263)化学構造

分子量(MW):974.61

Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。

サイズ 価格(税別)  
JPY 66400.00
JPY 19920.00
JPY 33200.00
JPY 61420.00
JPY 161020.00

文献中の使用例(37)

カスタマーフィードバック(13)

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

製品安全説明書

Bcl-2阻害剤の選択性比較

生物活性

製品説明 Navitoclax (ABT-263)は一種の有効なBcl-xL、Bcl-2とBcl-w阻害剤で、無細胞試験でKi値が0.5 nM及び0.5 nM以下、1nM及び1nM以下と1nM及び1nM以下にそれぞれ分かれることですが、Mcl-1、A1と結合する作用が少し弱いです。臨床2期。
ターゲット
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
体外試験

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkTWM2OD1yLkCwOlY6KM7:TR?= MWTTRW5ITVJ?
MV-4-11 M3q0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTtR|dJUUN3ME2wMlAyPTh4IN88US=> NVvIZ2hwW0GQR1XS
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfmXYxmUUN3ME2wMlAyPjl7IN88US=> Ml[1V2FPT0WU
ML-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPnUndSUUN3ME2wMlAyQTh|IN88US=> NIPuW4tUSU6JRWK=
BV-173 NWPKfJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXO[XVKSzVyPUCuNFI{OTRizszN M4La[3NCVkeHUh?=
RS4-11 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZSWlEPTB;MD6wNlU5PyEQvF2= MnfRV2FPT0WU
HL-60 M1izc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLJT|R1UUN3ME2wMlAzQTB6IN88US=> NIqwOHlUSU6JRWK=
KY821 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fxN2lEPTB;MD6wNlk4PSEQvF2= MYXTRW5ITVJ?
ECC10 M1rqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HMdWlEPTB;MD6wN|c6OiEQvF2= NELxfmRUSU6JRWK=
NCI-H720 NUjr[pR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrXS3dKSzVyPUCuNFQxOTFizszN MkXtV2FPT0WU
QIMR-WIL M13ZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG2TWM2OD1yLkC0Nlg4KM7:TR?= M4fCOHNCVkeHUh?=
KG-1 NF\LUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XCVGlEPTB;MD6wOFQ5PiEQvF2= MnXKV2FPT0WU
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\pW5RKSzVyPUCuNFQ3OzNizszN NYrmRVZ3W0GQR1XS
ATN-1 NUXPbmR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PtbGlEPTB;MD6wOFc{OyEQvF2= NIPacW1USU6JRWK=
RH-18 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfqZXdKSzVyPUCuNFYxPDhizszN MnToV2FPT0WU
EW-18 NFrQOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e3PWlEPTB;MD6wOlg1OSEQvF2= MVnTRW5ITVJ?
NB17 M{LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHkRYtKSzVyPUCuNFcyOjRizszN M1vxU3NCVkeHUh?=
SK-NEP-1 NIXHSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnlZ5VWUUN3ME2wMlA4OjF|IN88US=> MYrTRW5ITVJ?
P12-ICHIKAWA MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHWWZM4UUN3ME2wMlA4Pzd6IN88US=> MoqxV2FPT0WU
KARPAS-45 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnjTWM2OD1yLkC3PFE2KM7:TR?= NFTFdo9USU6JRWK=
EW-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDFTWM2OD1yLkC4NFU{KM7:TR?= MnrkV2FPT0WU
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fLPGlEPTB;MD6wPFIxOyEQvF2= NIHqcGVUSU6JRWK=
NCI-H209 NHTyeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK4b4pXUUN3ME2wMlA5PzB2IN88US=> NUfjPZVHW0GQR1XS
NCI-H1092 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzVOVdKSzVyPUCuNVAzPzVizszN NHLOWGFUSU6JRWK=
NH-12 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy1UoNqUUN3ME2wMlExPzR2IN88US=> MUHTRW5ITVJ?
697 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMUC4N|kh|ryP NYi2bplCW0GQR1XS
KE-37 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\GSWlEPTB;MD6xNVM4KM7:TR?= MYPTRW5ITVJ?
MOLT-4 NYj1PGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7PdmV7UUN3ME2wMlE2OTZ7IN88US=> NHjUeo9USU6JRWK=
CHP-134 M3vmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\zTWM2OD1yLkG2N|A3KM7:TR?= NFrvOGtUSU6JRWK=
D-283MED M1KzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTxTWM2OD1yLkG3Olg3KM7:TR?= NIXq[GtUSU6JRWK=
LU-135 NWPKd5BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn5N5BKSzVyPUCuNVg2PTJizszN Ml7sV2FPT0WU
LU-134-A MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL4NFdmUUN3ME2wMlE5PjdzIN88US=> NIS3bXdUSU6JRWK=
EM-2 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfWRpVPUUN3ME2wMlE6QTF6IN88US=> Mo[zV2FPT0WU
LU-139 NIeyNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3TWM2OD1yLkKwOFk5KM7:TR?= M4PFZ3NCVkeHUh?=
ALL-PO Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjNVGRlUUN3ME2wMlIyQTh6IN88US=> NWPQNJJ3W0GQR1XS
NB12 NWn3WI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTuZWlKSzVyPUCuNlMyOTVizszN MnHtV2FPT0WU
KP-N-YN MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHNdVRUUUN3ME2wMlI{PTd|IN88US=> MVXTRW5ITVJ?
BEN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorvTWM2OD1yLkKzPVY5KM7:TR?= M1Wxd3NCVkeHUh?=
HCC1569 NW[3XVBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH30N5FKSzVyPUCuNlUyODZizszN NFvFW2xUSU6JRWK=
HuO9 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED3XG9KSzVyPUCuNlY4OTVizszN MkjLV2FPT0WU
WM-115 M2P0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMke3N|gh|ryP MV;TRW5ITVJ?
CCRF-CEM NW\3XXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\XOGl5UUN3ME2wMlM{PTJ7IN88US=> MYLTRW5ITVJ?
IST-SL1 NF6zS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jLW2lEPTB;MD6zOVM1OyEQvF2= MVTTRW5ITVJ?
BE-13 NGTyem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2wXpNKSzVyPUCuN|Y1PTlizszN Mm\6V2FPT0WU
COR-L88 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwM{[1OEDPxE1? MUjTRW5ITVJ?
DOHH-2 NGmxbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7ETWM2OD1yLkSxNFI{KM7:TR?= M13ZZ3NCVkeHUh?=
A704 NIrxb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\ZZW1KSzVyPUCuOFI3PyEQvF2= MnzGV2FPT0WU
KNS-81-FD NEnXd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLtWXJZUUN3ME2wMlQ1ODF5IN88US=> NFzhZ5lUSU6JRWK=
RPMI-8226 NEDFTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrrTWM2OD1yLkS1OlUzKM7:TR?= M3XTc3NCVkeHUh?=
TGBC24TKB NVnS[oI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\IVIllUUN3ME2wMlQ2Pzd6IN88US=> MkjPV2FPT0WU
NCI-H1304 M1HlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNE[xOVch|ryP MXfTRW5ITVJ?
MOLT-13 NYTrcFh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nN[WlEPTB;MD60OlYyOyEQvF2= NYTOS3p3W0GQR1XS
EW-22 M3r5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPB[2ZKUUN3ME2wMlQ3PjdzIN88US=> NH;oVHdUSU6JRWK=
MS-1 M1zYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X1Z2lEPTB;MD60Olk{OyEQvF2= M2XQT3NCVkeHUh?=
RMG-I NED6dWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iw[GlEPTB;MD60PVQ3PCEQvF2= MUTTRW5ITVJ?
NTERA-S-cl-D1 NHnxfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;s[ZRKSzVyPUCuOVAxOTlizszN NWj6bXA2W0GQR1XS
NCI-H1048 M3vPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNUC5OVMh|ryP NVfodFRpW0GQR1XS
SW1417 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH4TWM2OD1yLkW1OFM5KM7:TR?= M2K2S3NCVkeHUh?=
DB NGm2enhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi5TI4{UUN3ME2wMlU4ODhizszN MlLFV2FPT0WU
MEG-01 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmySmNKSzVyPUCuOVg{OiEQvF2= NFXk[W1USU6JRWK=
EW-13 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki1TWM2OD1yLkW4N|QyKM7:TR?= M2flSXNCVkeHUh?=
LAMA-84 NFzaVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GyR2lEPTB;MD61PVIxPyEQvF2= M{\ObXNCVkeHUh?=
J-RT3-T3-5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNkC4NFgh|ryP M1O5XHNCVkeHUh?=
MOLT-16 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDrfXdKSzVyPUCuOlUzPjRizszN M4Hre3NCVkeHUh?=
DU-4475 NVTNZnVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnOOVVKSzVyPUCuOlU1OjdizszN MXLTRW5ITVJ?
HAL-01 NX7kd2Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwN{K1OFkh|ryP MnLUV2FPT0WU
RD NVHtdmpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfTcFZKSzVyPUCuO|U5QTlizszN M3fpdnNCVkeHUh?=
OAW-28 NIiyeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G1UGlEPTB;MD63PFM4KM7:TR?= NVTFXJJNW0GQR1XS
HCC38 NEP2PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwOECxPUDPxE1? NVX6XGg3W0GQR1XS
NMC-G1 NH7GTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK3TWM2OD1yLkixNVIyKM7:TR?= M3P0V3NCVkeHUh?=
EW-16 M1j2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfPO3ZKSzVyPUCuPFE{OjhizszN NX;oT4RSW0GQR1XS
DU-145 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXZR2hKSzVyPUCuPFk6OjNizszN Moi4V2FPT0WU
HPAF-II NVLpR2t6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwOUK2Nlgh|ryP NGjuVlFUSU6JRWK=
A427 NIHFboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUOwNlIh|ryP MlfvV2FPT0WU
PA-1 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVztXW1HUUN3ME2wMlk2PjR{IN88US=> NH7PfHhUSU6JRWK=
OAW-42 NEHINohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwOU[xOFYh|ryP MknuV2FPT0WU
L-428 NIew[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwMEGyOUDPxE1? MkXHV2FPT0WU
COLO-824 M3LGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXuRWVKSzVyPUGuNFE4ODhizszN MkSyV2FPT0WU
P30-OHK MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSwWGlKSzVyPUGuNFQ3QDhizszN MlzTV2FPT0WU
NCI-H2170 NX;qNY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzlZ5d[UUN3ME2xMlA3OjNizszN MVLTRW5ITVJ?
HCC2998 NV;UUlZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRTFd{UUN3ME2xMlA4OTN3IN88US=> MW\TRW5ITVJ?
NB14 M{X4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3hTWM2OD1zLkGzO|Q5KM7:TR?= Mn7RV2FPT0WU
TGBC1TKB NWLJ[257T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMUSxOVIh|ryP NHOwNXVUSU6JRWK=
KP-N-YS MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPkTWM2OD1zLkG2NlM3KM7:TR?= MkDwV2FPT0WU
CAL-120 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCyTWM2OD1zLkG2OFI6KM7:TR?= NX\EZ|ZCW0GQR1XS
SBC-1 NFO5SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjuTWM2OD1zLkG5NFU{KM7:TR?= MnPuV2FPT0WU
C32 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPnTWM2OD1zLkG5NFg5KM7:TR?= Mo\BV2FPT0WU
HCC2157 NEDuN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpS5lKSzVyPUGuNVk1QTRizszN MnLVV2FPT0WU
COLO-792 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S2[2lEPTB;MT6yNFA4OSEQvF2= M3HTdHNCVkeHUh?=
ES7 NHvWTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMke5OVEh|ryP NWD4Z44xW0GQR1XS
HEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf1RVZvUUN3ME2xMlMyODJ7IN88US=> M1XxeXNCVkeHUh?=
ES4 NH;ZN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fOUGlEPTB;MT6zOFk6QCEQvF2= NIPoXoxUSU6JRWK=
NCI-SNU-1 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i4emlEPTB;MT6zOlU2PSEQvF2= MmHLV2FPT0WU
MDA-MB-415 NXvtfHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jJcmlEPTB;MT6zPFg2KM7:TR?= M4HFPXNCVkeHUh?=
NCI-H2342 NXTY[ZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\WN2ZFUUN3ME2xMlQxOjZ7IN88US=> M3XJNnNCVkeHUh?=
NB69 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqOpZIUUN3ME2xMlQ3OjdzIN88US=> Mn36V2FPT0WU
D-247MG M33INWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzfYlKUUN3ME2xMlUyOTJ{IN88US=> M3nFeHNCVkeHUh?=
SCC-4 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwNUm4PFch|ryP MUjTRW5ITVJ?
HuH-7 NH3oSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwNkeyPVMh|ryP M1HpWHNCVkeHUh?=
A388 NUjwcmVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwNki3NlQh|ryP NYf4VGxMW0GQR1XS
Calu-3 M{PobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjaTok{UUN3ME2xMlcxPjl5IN88US=> M4XEN3NCVkeHUh?=
NCI-H1648 M2fM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XC[WlEPTB;MT63NVQyQCEQvF2= M4rzXXNCVkeHUh?=
NCI-H2052 NX;qfVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGzfHJTUUN3ME2xMlczOjBzIN88US=> NEW3UXJUSU6JRWK=
Ramos-2G6-4C10 M4\MWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK2eIRKSzVyPUGuO|M3PTZizszN M{XhSHNCVkeHUh?=
DEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwN{S2PVIh|ryP MoXLV2FPT0WU
SNU-423 NU\VeFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwN{ixOVch|ryP NYjwXZl3W0GQR1XS
COR-L23 M3izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3DTWM2OD1zLke5PFc1KM7:TR?= NYXJd5NxW0GQR1XS
OMC-1 NHHrTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwOE[wNVYh|ryP Mn\mV2FPT0WU
EW-11 NV[5dIl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjVe25rUUN3ME2xMlk2PjV5IN88US=> M1PHfnNCVkeHUh?=
HSC-3 NYeyZ2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjDTGduUUN3ME2xMlk3OzZ3IN88US=> M2raZ3NCVkeHUh?=
MLMA M{HTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HYW2lEPTB;MT65OlY4PyEQvF2= Mn;BV2FPT0WU
RCM-1 NXXLSXFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwMECzPVkh|ryP MXrTRW5ITVJ?
MFE-280 NETnUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHqTWM2OD1{LkCyPFQ5KM7:TR?= NWTNNmhNW0GQR1XS
ES8 NEnvRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HsZ2lEPTB;Mj6yOVQ4OSEQvF2= MYLTRW5ITVJ?
TE-11 NV63VWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS1OYxKSzVyPUKuNlk1PzNizszN MmjHV2FPT0WU
HuO-3N1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;hcGlEPTB;Mj60PFc5KM7:TR?= MkTQV2FPT0WU
MHH-NB-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXWWINKSzVyPUKuOVEyPThizszN M37FbHNCVkeHUh?=
TGBC11TKB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nqeWlEPTB;Mj61O|Y5OSEQvF2= MU\TRW5ITVJ?
HOP-92 NVyySVFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;MdopKSzVyPUKuOVg4PDNizszN M4nK[nNCVkeHUh?=
IGR-1 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX25Vlg3UUN3ME2yMlYzODN3IN88US=> MV3TRW5ITVJ?
GOTO M1HPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwNkWzO|ch|ryP MXPTRW5ITVJ?
NCI-H1650 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzZTWM2OD1{LkeyNlE2KM7:TR?= MVrTRW5ITVJ?
NCI-H1581 NWTKblBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7uTWM2OD1{Lke5OlgyKM7:TR?= NUjUTIZmW0GQR1XS
NCI-H2405 M2Dwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTFdWhOUUN3ME2yMlgzPzh{IN88US=> NXvE[3ZHW0GQR1XS
U-118-MG M3jpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TQc2lEPTB;Mj65OlQ6OSEQvF2= NF3URo9USU6JRWK=
DoTc2-4510 M{TkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTNwMEG0NVch|ryP MWHTRW5ITVJ?
NCI-H596 NIS1cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfwd4k4UUN3ME2zMlA1QTl5IN88US=> M3zVVHNCVkeHUh?=
MPP-89 NEnMRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF20clZKSzVyPUOuNFU3PjZizszN NX:2WY05W0GQR1XS
GCIY MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XtR2lEPTB;Mz6yNFQ6OSEQvF2= NXr4NHJzW0GQR1XS
SW626 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fOXWlEPTB;Mz6yOFU1OyEQvF2= NWXuNoF1W0GQR1XS
OCI-AML2 M1TCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTXTWM2OD1|LkOxNlczKM7:TR?= NWi5[4lWW0GQR1XS
NBsusSR M3zmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNwM{S5N|gh|ryP M1;ufHNCVkeHUh?=
AN3-CA NEHYRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTLTWM2OD1|LkS0NlM5KM7:TR?= MlTTV2FPT0WU
EFM-19 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\BO2lEPTB;Mz60PFM{QSEQvF2= NUDOb2NtW0GQR1XS
RVH-421 NW\pTXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX60fJhtUUN3ME2zMlU3QDd5IN88US=> NVvQdmN4W0GQR1XS
5637 NWDmbIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnDUZI6UUN3ME2zMlYyOTB|IN88US=> NWPy[3VOW0GQR1XS
PANC-08-13 M1jFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNwNkO0O|Ih|ryP MX3TRW5ITVJ?
H9 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yO3FzUUN3ME2zMlY4OTR2IN88US=> Mk\5V2FPT0WU
KARPAS-299 M2TCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T2ZWlEPTB;Mz62O|M3OSEQvF2= NUC0eWNzW0GQR1XS
TE-5 NEj3UpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDkTWM2OD1|LkewO|A6KM7:TR?= MlLQV2FPT0WU
NOS-1 M2PwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HwRmlEPTB;Mz63PVg{PCEQvF2= M17BNnNCVkeHUh?=
HH Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXwTWM2OD1|LkizPFY5KM7:TR?= M1XJXXNCVkeHUh?=
769-P M{DkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNwOEm1NUDPxE1? NES2T21USU6JRWK=
CHP-212 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLLTWM2OD1|LkmyOVQ6KM7:TR?= MYnTRW5ITVJ?
NCI-H82 M2XFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\v[4xKSzVyPUOuPVU6OzZizszN MkHrV2FPT0WU
Mo-T NHuwXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXpTWM2OD12LkC0N|EzKM7:TR?= MYLTRW5ITVJ?
BB65-RCC NWrwWFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTRwMESzPVkh|ryP MXzTRW5ITVJ?
SW1990 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXkblA4UUN3ME20MlA2QTB6IN88US=> NWK3U3pZW0GQR1XS
LK-2 NGjvPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTRwMUGyPVMh|ryP NXLpWoxDW0GQR1XS
ES5 M2LhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\vWmlEPTB;ND6xN|k5PSEQvF2= M2G4eXNCVkeHUh?=
JVM-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTRwMUiyNlIh|ryP NFTPO3lUSU6JRWK=
RPMI-7951 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRwMkK0NVMh|ryP MY\TRW5ITVJ?
Calu-6 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj5XWJ7UUN3ME20MlI4QDhzIN88US=> MXPTRW5ITVJ?
LC-2-ad MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW1bnZKSzVyPUSuNlk2PjhizszN MW\TRW5ITVJ?
SW954 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDD[WRKSzVyPUSuNlk3PiEQvF2= M{SzTHNCVkeHUh?=
H-EMC-SS NVrRSHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPXTWM2OD12LkOxPFMyKM7:TR?= MlfvV2FPT0WU
ES3 M4[yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3JOINKSzVyPUSuN|U1PDFizszN MXXTRW5ITVJ?
no-11 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rLSGlEPTB;ND6zOVU2PCEQvF2= M{PoXHNCVkeHUh?=
LAN-6 NYi2fHo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ftU2lEPTB;ND60OVE5QSEQvF2= NEX1Z4ZUSU6JRWK=
FTC-133 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwNUO5OUDPxE1? NHjyUJBUSU6JRWK=
8505C MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITMfpdKSzVyPUSuOVQzOyEQvF2= M1TF[HNCVkeHUh?=
SW620 NVH1TXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;seJFSUUN3ME20MlU4ODV5IN88US=> NXvjbW1lW0GQR1XS
BCPAP MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\2TmVLUUN3ME20MlY{PDhzIN88US=> NFHNTZFUSU6JRWK=
SK-LU-1 NX70dGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLXbFJrUUN3ME20MlY3ODh7IN88US=> NULjU3FsW0GQR1XS
NCI-H1623 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXjenZUUUN3ME20MlcxOjJ6IN88US=> NULWe291W0GQR1XS
C2BBe1 M3P4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LDeWlEPTB;ND63OFAxQCEQvF2= M1K3NHNCVkeHUh?=
GP5d NGDKNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHvUndqUUN3ME20Mlc5Ozh6IN88US=> Mn\qV2FPT0WU
NB6 NHHhS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfhfmxKSzVyPUSuPFYzODRizszN NE[weZRUSU6JRWK=
MDA-MB-157 NF7qU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3XdXVKSzVyPUSuPFg4PiEQvF2= MoG5V2FPT0WU
UMC-11 NFPER3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTRwOEi5OlQh|ryP M2LURXNCVkeHUh?=
HCC1419 NF;vWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofpTWM2OD12LkmwNFY{KM7:TR?= MoeyV2FPT0WU
NCI-H2029 NFT2NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPaVWFKSzVyPUSuPVQyQDVizszN MX3TRW5ITVJ?
LXF-289 M1TZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq1OYRsUUN3ME21MlA{PzF7IN88US=> NF\4dpVUSU6JRWK=
KINGS-1 NVzHepdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTVwMEe3OFQh|ryP M2ftOXNCVkeHUh?=
HD-MY-Z MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwMkO5Olkh|ryP NYjGdWk1W0GQR1XS
ESS-1 NVzqW3l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwMkW1PVch|ryP MVPTRW5ITVJ?
GI-1 NYjMdZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVwMke5NlYh|ryP NUnlepllW0GQR1XS
RPMI-2650 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLNcIRLUUN3ME21MlM3OTZizszN MlLEV2FPT0WU
IA-LM NUGxc5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3hSldoUUN3ME21MlM6QDdzIN88US=> NYPkSYp2W0GQR1XS
KP-4 NFnPeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXkbmxTUUN3ME21MlQ3OzN2IN88US=> MmjOV2FPT0WU
G-402 NXjsbpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L3OmlEPTB;NT61NVg3PSEQvF2= NYHYNlQyW0GQR1XS
OS-RC-2 M2X3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLTWI9kUUN3ME21MlUzPjB2IN88US=> NX:zS2EyW0GQR1XS
NCI-H1155 M1nROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTVwNUS5OVUh|ryP NH\iXFlUSU6JRWK=
OE19 M4HpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH2OldKSzVyPUWuOlg3OjRizszN NVWyVG0yW0GQR1XS
U-2-OS MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHLTWM2OD13Lki5NFE{KM7:TR?= NHX3NYNUSU6JRWK=
SCC-15 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwOUO2OlIh|ryP NF\aVIFUSU6JRWK=
NCI-H630 M{PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfMTWM2OD13Lkm5OFA1KM7:TR?= MlnuV2FPT0WU
PFSK-1 NHrXXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZwMEWyOVkh|ryP NGrFXmFUSU6JRWK=
NCI-H1770 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTETGJKSzVyPU[uNlA5PzRizszN M4fOSXNCVkeHUh?=
SK-MEL-3 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXJfmFJUUN3ME22MlQzQTF3IN88US=> MW\TRW5ITVJ?
LB1047-RCC NXLUb2x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTZwNEe2NlUh|ryP M3noZ3NCVkeHUh?=
NCI-H446 M4GwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZwNkK5NlUh|ryP M1LkNnNCVkeHUh?=
SW780 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:xUYNxUUN3ME22MlcxOTh3IN88US=> NHTBdoVUSU6JRWK=
NEC8 NXjvdY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD6TWM2OD14Lke2OlMh|ryP MknJV2FPT0WU
NOMO-1 NVj6V|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZwN{ixNVEh|ryP NEH4cVBUSU6JRWK=
COLO-668 NEfm[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwOESzPFch|ryP Ml\uV2FPT0WU
MC116 NF7BSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\kN2dqUUN3ME22Mlk{QDl5IN88US=> MYfTRW5ITVJ?
HCC1937 M{SzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1npSGlEPTB;Nj65PVI2OSEQvF2= NF3DUI9USU6JRWK=
NCI-N87 NE\Lb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr4XWxKSzVyPUeuNVkzQTNizszN MnfwV2FPT0WU
COLO-320-HSR M3fKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\uWJc6UUN3ME23MlIzPzN6IN88US=> MmjZV2FPT0WU
HCC1806 NGDycFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdwMk[wOFQh|ryP Mk[1V2FPT0WU
OVCAR-3 M{L2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHsR|JKSzVyPUeuN|MxOzhizszN MUHTRW5ITVJ?
NUGC-3 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TrS2lEPTB;Nz6zPVY6PCEQvF2= MljvV2FPT0WU
SW1783 M2i4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLxTWM2OD15LkSzNVc2KM7:TR?= NFrHeWJUSU6JRWK=
GCT NVLodYp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2eyPGlEPTB;Nz61OlkxPiEQvF2= MmH0V2FPT0WU
NCI-H2126 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnQbmRjUUN3ME23Mlc{PjJ3IN88US=> M1uzOHNCVkeHUh?=
MEL-HO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvWWmpKSzVyPUeuO|cxPTRizszN NVnUZnNZW0GQR1XS
CAPAN-1 NG\mcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTdwN{ezOVch|ryP NGj6ZYZUSU6JRWK=
SW756 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi0TXJKSzVyPUeuO|g{OzNizszN NF7Cb3ZUSU6JRWK=
SKG-IIIa MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LvWGlEPTB;Nz64NVg6OiEQvF2= NXW1eGRNW0GQR1XS
HCE-T NYPaRYllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPDZnZiUUN3ME23Mlg4Pzh|IN88US=> NXnqOFRZW0GQR1XS
Ca-Ski MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XS[WlEPTB;Nz65PVM5OyEQvF2= NEjV[GRUSU6JRWK=
COLO-684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwMEG4NVgh|ryP MnHTV2FPT0WU
KYSE-70 NYTIW|FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRThwMEe3Nlkh|ryP NFzVVpJUSU6JRWK=
TI-73 NEPr[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jn[2lEPTB;OD6yOVg2OSEQvF2= M4\sR3NCVkeHUh?=
BT-20 NYLxZ3FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjzfoo3UUN3ME24MlI3ODV{IN88US=> M2\tbHNCVkeHUh?=
MHH-ES-1 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRThwNUG4N|Qh|ryP NIX1d5dUSU6JRWK=
TE-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGzTWM2OD16LkW5PVMyKM7:TR?= MoL4V2FPT0WU
YH-13 NYTRSlBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRThwNkGwNFgh|ryP NELjdpFUSU6JRWK=
SF126 NE\xRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD3PWlzUUN3ME24Mlg{QDZ3IN88US=> M1;3VXNCVkeHUh?=
J82 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXGTWM2OD16LkmwNFM5KM7:TR?= Mkn0V2FPT0WU
RCC10RGB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyxSmdKSzVyPUiuPVk2PjFizszN MV3TRW5ITVJ?
SK-UT-1 M2rkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofLTWM2OD17LkC0PVQ2KM7:TR?= MoX1V2FPT0WU
LB2241-RCC NHzDUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTlwMUmxN|ch|ryP NGHPWo1USU6JRWK=
LB996-RCC NF3FXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HncmlEPTB;OT6xPVg6KM7:TR?= MXHTRW5ITVJ?
EPLC-272H NF\WXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTlwM{e2OVch|ryP NWXXS4tiW0GQR1XS
CTV-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Kc2dSUUN3ME25MlU3PTN{IN88US=> M3u5UnNCVkeHUh?=
HSC-2 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDtTYpKSzVyPUmuOVc2PSEQvF2= MYHTRW5ITVJ?
SK-MEL-28 NYTsZ2toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke1TWM2OD17Lk[xPFk{KM7:TR?= M2n5NnNCVkeHUh?=
MMAC-SF NIfsOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUKzTmhJUUN3ME25MlY5PzVizszN M4TIPXNCVkeHUh?=
CP50-MEL-B NWfz[YZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ndHlKSzVyPUmuO|U4QDJizszN NHPPXFNUSU6JRWK=
HT-1080 M1fGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TmNGlEPTB;OT63O|c{QSEQvF2= M2rzZ3NCVkeHUh?=
HEC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z3RWlEPTB;MUCuN|M2OiEQvF2= MWnTRW5ITVJ?
AGS NIfaNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrR[o5KSzVyPUGwMlM4PCEQvF2= M4TD[3NCVkeHUh?=
GAMG M1jHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFyLkWxOlIh|ryP MWLTRW5ITVJ?
SW48 M{fzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf4TWM2OD1zMD61NVg6KM7:TR?= M1n4b3NCVkeHUh?=
U031 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFyLkW5NFgh|ryP M37LfnNCVkeHUh?=
OVCAR-5 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rQVmlEPTB;MUCuOlQzQSEQvF2= MXfTRW5ITVJ?
SF295 NYLjR41vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFyLk[3NFQh|ryP NILwN5VUSU6JRWK=
BHT-101 NHTkcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LaTmlEPTB;MUCuO|E4PyEQvF2= M2fVRnNCVkeHUh?=
VMRC-RCZ M3nURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFzLkOyNFEh|ryP MUDTRW5ITVJ?
ACHN Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzLkSyNVEh|ryP M2H4dXNCVkeHUh?=
NCI-H526 NYn3dIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjac3Y{UUN3ME2xNU42ODR|IN88US=> NGC5SnpUSU6JRWK=
MN-60 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFzLkWzPUDPxE1? MnX1V2FPT0WU
NCI-H2291 NUDZXmtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFzLkW0OlYh|ryP NFXpN3BUSU6JRWK=
SCC-25 M3fvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzvTWM2OD1zMT63OVU3KM7:TR?= MUTTRW5ITVJ?
SK-MEL-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDic21MUUN3ME2xNU44PjN5IN88US=> MUXTRW5ITVJ?
SN12C NIPZ[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITKS|NKSzVyPUGxMlk{PTVizszN MnnrV2FPT0WU
NCI-H69 NIL6cHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\5WGlEPTB;MUKuOFI{PCEQvF2= MWPTRW5ITVJ?
ME-180 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF{LkewOVQh|ryP MoLKV2FPT0WU
MC-IXC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF{Lke1NVgh|ryP MnvzV2FPT0WU
NCI-H2347 M{jabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfFUFJKSzVyPUGyMlc3OTRizszN NVPHPGljW0GQR1XS
M059J MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF{Lke3Nlch|ryP NH\pSodUSU6JRWK=
A2058 NVvqRYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7oS2hKSzVyPUGyMlg3QDFizszN NWj1WIZnW0GQR1XS
VA-ES-BJ NX;Ob5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXUVI5KSzVyPUGyMlg4QDVizszN M2GwcXNCVkeHUh?=
Ca9-22 NIjFU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XrPWlEPTB;MUKuPVQ2OSEQvF2= MV3TRW5ITVJ?
KNS-42 NIfuVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5OWlEPTB;MUKuPVk5PCEQvF2= M3exfnNCVkeHUh?=
LoVo M{e3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF|LkKzNVMh|ryP MV;TRW5ITVJ?
AM-38 NIP1VnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF|LkK1OlYh|ryP NG[4UG1USU6JRWK=
NB5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LscWlEPTB;MUOuN|c2OiEQvF2= M1nEcXNCVkeHUh?=
L-363 M3j6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF|LkSwN|Mh|ryP MojDV2FPT0WU
SK-MEL-30 NFjHclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF2LkC2OFUh|ryP MV3TRW5ITVJ?
NCI-H1563 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF2Lk[wN|kh|ryP MlywV2FPT0WU
NCI-H2228 NFvwWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF2Lk[wO|ch|ryP MYrTRW5ITVJ?
MFM-223 NFjtTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHmTWM2OD1zNT6xPFE{KM7:TR?= NWPlcI1CW0GQR1XS
LB831-BLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjmOFRKSzVyPUG1MlI4PjdizszN MUHTRW5ITVJ?
SW872 NGezZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfJUZhyUUN3ME2xOU4{ODh4IN88US=> NYjvZnVkW0GQR1XS
NCI-H522 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjvfmNKSzVyPUG1MlM{ODZizszN NIrrNHFUSU6JRWK=
EW-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rBbWlEPTB;MUWuOVQ3OiEQvF2= Ml\IV2FPT0WU
HN MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF3LkW5OFIh|ryP M{LpR3NCVkeHUh?=
SW837 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XmbGlEPTB;MUWuO|g1PyEQvF2= MlzuV2FPT0WU
SCC-9 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XNO2lEPTB;MUWuPFEyPCEQvF2= MojDV2FPT0WU
MKN7 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\o[YtKSzVyPUG1Mlk4OzJizszN MVvTRW5ITVJ?
KYSE-410 NWS0SGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrqO2VKSzVyPUG2MlU6OSEQvF2= MWHTRW5ITVJ?
SK-N-DZ NXTNU|ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j2W2lEPTB;MU[uOlEyPiEQvF2= NHL3T2xUSU6JRWK=
COR-L105 NVy4bYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEezXXNKSzVyPUG2MlY2OjhizszN MWHTRW5ITVJ?
LB2518-MEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF4LkizPFkh|ryP M2P3[nNCVkeHUh?=
OVCAR-4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m3d2lEPTB;MU[uPFg3OiEQvF2= Ml\6V2FPT0WU
TK10 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF4Lkm0O|Mh|ryP NV21epF6W0GQR1XS
KNS-62 M2TIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\s[GlEPTB;MU[uPVc4PyEQvF2= NWDwbmZ6W0GQR1XS
RPMI-8866 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF5LkG3N|Ih|ryP NFX6T2NUSU6JRWK=
HuP-T4 NGPzU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PPeWlEPTB;MUeuNlQ6PSEQvF2= NYf0TJR6W0GQR1XS
CGTH-W-1 NIfrOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuyR5VKSzVyPUG3MlUzOTlizszN MULTRW5ITVJ?
T-24 NXHmUJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF5LkWzOFch|ryP MnfXV2FPT0WU
HT-3 NEjVNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF5LkW5NVQh|ryP MmXJV2FPT0WU
KS-1 NH70R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXuTHFKSzVyPUG3MlY4OyEQvF2= MUHTRW5ITVJ?
NCI-H1792 NYnpbVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrJSI16UUN3ME2xO{44QThizszN NWmyW4U6W0GQR1XS
ABC-1 NG\IcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe3ZXNKSzVyPUG3MlgyPDFizszN NY\hOpRIW0GQR1XS
BPH-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PqXGlEPTB;MUiuNVY5PSEQvF2= NGLrUG1USU6JRWK=
A431 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrwTWM2OD1zOD60NVI4KM7:TR?= NHTzbIRUSU6JRWK=
T98G Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG0dmVKSzVyPUG4MlUyPTdizszN NHjPZZBUSU6JRWK=
BHY M3\0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\W[WlEPTB;MUiuPFY6KM7:TR?= MYDTRW5ITVJ?
Capan-2 NX70clE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTidINQUUN3ME2xPE46ODd6IN88US=> NXW2NWN6W0GQR1XS
MDA-MB-175-VII NXLHSFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP2TWM2OD1zOD65NlA6KM7:TR?= MnjZV2FPT0WU
CAL-27 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXNTWM2OD1zOT6wOFg4KM7:TR?= MYTTRW5ITVJ?
AsPC-1 M1\jUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\H[mlEPTB;MUmuPFY2PyEQvF2= MoTDV2FPT0WU
KU812 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\6Oo5jUUN3ME2xPU46PTd|IN88US=> M{DwXnNCVkeHUh?=
NCI-H441 NFrSSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJyLkCwNUDPxE1? NEHjXplUSU6JRWK=
Mewo M2fUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPCb45NUUN3ME2yNE4yOjh6IN88US=> MV;TRW5ITVJ?
SK-MEL-24 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjVTo5tUUN3ME2yNE4yPDd5IN88US=> NYjvXZdRW0GQR1XS
NCI-H727 NX7HdWh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrDTWM2OD1{MD6yO|A1KM7:TR?= NFfkR4dUSU6JRWK=
EKVX MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJyLk[wOkDPxE1? NWPHcpFNW0GQR1XS
RT-112 NVjrRWFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3zTWM2OD1{MD62NVIzKM7:TR?= Mmr3V2FPT0WU
CAMA-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpTWM2OD1{MD65PFA{KM7:TR?= MXvTRW5ITVJ?
SW900 M360PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\hfFFjUUN3ME2yNU4xOTR7IN88US=> MX;TRW5ITVJ?
NCI-H23 M{TZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnlNFZKSzVyPUKxMlEzPzdizszN MWjTRW5ITVJ?
SK-PN-DW NGDnWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJzLkG2OFkh|ryP MVjTRW5ITVJ?
BB30-HNC NIHrPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr3bGxKSzVyPUKxMlI4PDVizszN Mn:5V2FPT0WU
VM-CUB-1 NXqyXWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLyTWM2OD1{MT6zOVM3KM7:TR?= M2HwbnNCVkeHUh?=
IST-MEL1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PYdGlEPTB;MkGuN|Y6OiEQvF2= M2rkdHNCVkeHUh?=
CTB-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJzLkS3OVUh|ryP M2rOSnNCVkeHUh?=
LCLC-103H NUTvbZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOzTWM2OD1{Mj6xOVgzKM7:TR?= MnLJV2FPT0WU
PANC-03-27 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz6[HhrUUN3ME2yNk42OTZ7IN88US=> M{PBS3NCVkeHUh?=
HTC-C3 M3fne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXETWM2OD1{Mj61OVU2KM7:TR?= MXvTRW5ITVJ?
TE-8 M3fDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ|LkK1OlUh|ryP Ml3uV2FPT0WU
NCI-H292 NFLQbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3pTWM2OD1{NT6zOVM3KM7:TR?= M{K4SHNCVkeHUh?=
COLO-680N MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnEbY1KSzVyPUK1MlY{OjlizszN M1XsZXNCVkeHUh?=
KYSE-520 M1vxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PLSmlEPTB;MkWuOlQ1KM7:TR?= NX7rVVJ7W0GQR1XS
NB10 NXn0cZNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ4LkOxNVch|ryP NWjYb3RyW0GQR1XS
NCI-H661 NEDGb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ4LkS3NVMh|ryP NVvLcnlHW0GQR1XS
GMS-10 NILjSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LZN2lEPTB;Mk[uPFY{QCEQvF2= NYfyO2RJW0GQR1XS
NCI-H2122 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ4Lkm5PVgh|ryP Mnr2V2FPT0WU
OVCAR-8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jSfWlEPTB;MkeuNFY{QCEQvF2= MVXTRW5ITVJ?
DJM-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nlWGlEPTB;MkeuNVQ2PCEQvF2= NVr2UoxxW0GQR1XS
UACC-893 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ5Lkm4O|gh|ryP MXfTRW5ITVJ?
C8166 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;ETWM2OD1{OD62PVM5KM7:TR?= M4\2WHNCVkeHUh?=
NCI-H1693 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Kx[GlEPTB;MkiuOlk4PSEQvF2= M1:zWHNCVkeHUh?=
TYK-nu NX:yPJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LE[WlEPTB;M{CuNFM1PSEQvF2= NUXybHpKW0GQR1XS
SW1710 NYrpcWFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTDV4VKSzVyPUOwMlEzPiEQvF2= NGWxOIJUSU6JRWK=
A375 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP4d444UUN3ME2zNE4{OjR|IN88US=> M3rWVnNCVkeHUh?=
HMV-II NWTpR3BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjNWYZmUUN3ME2zNU4{PTl{IN88US=> NXX1NphSW0GQR1XS
NCI-H2087 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jkW2lEPTB;M{GuOlM2OiEQvF2= M3Hu[nNCVkeHUh?=
CAL-54 MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M376RmlEPTB;M{GuO|I1OSEQvF2= NUe5NY92W0GQR1XS
HCC70 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmexTWM2OD1|Mj6xN|g4KM7:TR?= NUfWPIk4W0GQR1XS
ES1 NFT1N4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN{LkOwOlIh|ryP MUfTRW5ITVJ?
NCI-H1355 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm4WmhjUUN3ME2zN{4zODRizszN NUXM[npMW0GQR1XS
CFPAC-1 NFrGXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN|LkKzN|Ih|ryP MoHDV2FPT0WU
MKN28 NXztboE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjZ[ZJ4UUN3ME2zN{4{QDB7IN88US=> M2niOXNCVkeHUh?=
HDLM-2 NWDiXodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLNO3YxUUN3ME2zN{43QTNzIN88US=> M4\S[3NCVkeHUh?=
PANC-10-05 M2jHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfScWdjUUN3ME2zOE4yODF2IN88US=> NInnUIZUSU6JRWK=
SAS Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDkSVZKSzVyPUO0MlQ2PjVizszN NYXwcm5iW0GQR1XS
HCC1395 NEnuNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{npRmlEPTB;M{SuO|E5PiEQvF2= MXrTRW5ITVJ?
8305C MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfvbYVvUUN3ME2zOU45PDF3IN88US=> NX7YcWc3W0GQR1XS
KM12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq5TWM2OD1|Nj63OVQ4KM7:TR?= NV7ISVlvW0GQR1XS
SW1116 M3T5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jUemlEPTB;M{euOVk6OiEQvF2= MoDCV2FPT0WU
SK-MEL-1 NIPmOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zpcGlEPTB;M{iuN|M5QSEQvF2= NICyNJZUSU6JRWK=
HCC2218 NFH6UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;ZcWlEPTB;M{iuOlUyQSEQvF2= M2i1TXNCVkeHUh?=
T84 NGjXVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\BXIdKSzVyPUO4Mlc1ODlizszN MVjTRW5ITVJ?
ETK-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjlOpc{UUN3ME2zPU4xOjJizszN NWrMR405W0GQR1XS
COLO-800 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTEc2NtUUN3ME2zPU4{QDZ6IN88US=> M{faNXNCVkeHUh?=
CAL-12T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH70W2hKSzVyPUO5MlUzQDFizszN NHjpcGxUSU6JRWK=
ACN M3nzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[5UWhKSzVyPUSwMlQ6OTFizszN M3;wSXNCVkeHUh?=
SJSA-1 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTRzLkG1PVYh|ryP NYWzbHE5W0GQR1XS
PSN1 M4fBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GwW2lEPTB;NEGuNVc1QSEQvF2= MWjTRW5ITVJ?
D-566MG NFHCTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mUWdKSzVyPUSxMlIxQDZizszN NWH1enBMW0GQR1XS
EGI-1 NUnz[4JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\UN49bUUN3ME20Nk41OjhizszN NEDtNZBUSU6JRWK=
A204 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO2TYFKSzVyPUSyMlY{QDhizszN MoG3V2FPT0WU
Saos-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ftWWlEPTB;NEKuPFM3QSEQvF2= MnzxV2FPT0WU
SNU-C2B NVLoUZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR|Lk[4O|gh|ryP MnG1V2FPT0WU
HLE MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfBTWM2OD12ND6wPFU3KM7:TR?= MnO3V2FPT0WU
SW1463 M4T3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:1TWM2OD12ND65PVcyKM7:TR?= M17ZcHNCVkeHUh?=
DSH1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;xPINjUUN3ME20OU4xODN|IN88US=> NY[1cWFMW0GQR1XS
MCF7 NFfPXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TEW2lEPTB;NEWuOVA2OSEQvF2= NIHUVohUSU6JRWK=
K5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K5W2lEPTB;NEWuPVQxPSEQvF2= MmL5V2FPT0WU
NCI-H358 NH7JfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnzeZJKSzVyPUS3MlIyPSEQvF2= MmjlV2FPT0WU
NCI-H2030 M4HSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLDVFVlUUN3ME20O{4zOzd2IN88US=> NU\rVFVwW0GQR1XS
SW948 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Kw[2lEPTB;NEeuOFY1KM7:TR?= MVHTRW5ITVJ?
BALL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rhPWlEPTB;NEeuOlE3QCEQvF2= MYrTRW5ITVJ?
TE-9 M4HVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzX[|FKSzVyPUS3Mlk2QDFizszN NUTOWWNFW0GQR1XS
SK-N-FI M2frSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\peIJKSzVyPUS4MlA{PThizszN M4PXZnNCVkeHUh?=
KALS-1 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33tNWlEPTB;NEiuNVI5QSEQvF2= MWLTRW5ITVJ?
HO-1-N-1 NUiybmZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;EWIRzUUN3ME20PE44PDR3IN88US=> M4XJfnNCVkeHUh?=
NCI-H2452 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS4XmNVUUN3ME20PU4yOTV{IN88US=> M2\EfnNCVkeHUh?=
OC-314 NH\yfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR7Lk[4N|Qh|ryP NV[3SJIyW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
細胞試験:

[1]

+ 展開
  • 細胞株: SCLC cell lines
  • 濃度: 0-1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: C.B.-17 scid-bg or C.B.-17 scid mice
  • 製剤: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • 投薬量: 100 mg/kg/d
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+corn oil
7mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • 回答:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • 問題2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • 回答:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Related Antibodies

Bcl-2信号経路図

Bcl-2 Inhibitors with Unique Features

相関Bcl-2製品

Tags: Navitoclax (ABT-263)を買う | Navitoclax (ABT-263) ic50 | Navitoclax (ABT-263)供給者 | Navitoclax (ABT-263)を購入する | Navitoclax (ABT-263)費用 | Navitoclax (ABT-263)生産者 | オーダーNavitoclax (ABT-263) | Navitoclax (ABT-263)化学構造 | Navitoclax (ABT-263)分子量 | Navitoclax (ABT-263)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID